Monclonal antibodies are valuable reagents to study molecular mechanisms of the neurodegenerative diseases Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD).
The Core Facility ‘Monoclonal Antibodies’ of the German Center for Neurodegenerative Diseases (DZNE), which is located at the Helmholtz Zentrum München in Neuherberg, generates custom-made monoclonal antibodies in collaboration with partners at the DZNE and for other research institutions. We screen several thousand antibody clones per antigen in high-throughput ELISA for specific antibody production. All positively-tested clones are expanded for further validation by the individual scientist in the desired assay, such as immunoblotting, immunofluorescence, immunoprecipitation, and FACS analysis. Once established, these antibodies provide an unlimited source of highly specific reagents for the detection of disease-linked proteins in in vitro and in vivo models, in diagnostic assays, and also for immunotherapeutic approaches.
The portfolio or the Antibody Core Facility encompasses advice on antigen design, immunisation, screening and establishment of custom-made monoclonal antibodies. Furthermore, we perform large-scale antibody purification and antibody labelling.
More information can be found here: https://www.helmholtz-munich.de/en/core-facility-overview/monoclonal-antibodies